Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma

BACKGROUND: Recent reports of the utilisation of pyrvinium pamoate (PP), an FDA-approved anti-helminth, have shown that it inhibits pancreatic ductal adenocarcinoma (PDAC) cell growth and proliferation in-vitro and in-vivo in preclinical models. Here, we report about an ongoing phase I open-label, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponzini, Francesca M, Schultz, Christopher W, Leiby, Benjamin E, Cannaday, Shawnna, Yeo, T, Posey, James, Bowne, Wilbur B, Yeo, Charles, Brody, Jonathan R, Lavu, Harish, Nevler, Avinoam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582846/
https://www.ncbi.nlm.nih.gov/pubmed/37848297
http://dx.doi.org/10.1136/bmjopen-2023-073839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582846/
https://www.ncbi.nlm.nih.gov/pubmed/37848297
http://dx.doi.org/10.1136/bmjopen-2023-073839

Ejemplares similares